Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.58 |
| ▸ | CALML3 | P27482 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017577 | 0.89 | MAOA (0.55) | MAOACALML3 | |
| SCHEMBL5656454 | 0.89 | CALML3 (0.47) | MAOACALML3MAOB | |
| SCHEMBL5235196 | 0.86 | MAOA (0.59) | MAOACALML3MAOB | |
| SCHEMBL14525402 | 0.85 | MAOA (0.51) | MAOACALML3 | |
| SCHEMBL5232671 | 0.83 | MAOA (0.52) | MAOACALML3MAOB | |
| SCHEMBL3039711 | 0.83 | MAOA (0.52) | MAOACALML3 | |
| SCHEMBL5233962 | 0.82 | MAOA (0.58) | MAOACALML3MAOB | |
| SCHEMBL5232210 | 0.82 | MAOA (0.80) | MAOAMAOB | |
| SCHEMBL5658913 | 0.81 | MAOA (0.71) | MAOACALML3MAOB | |
| SCHEMBL7078321 | 0.81 | MAOA (0.48) | MAOACALML3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081403-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2020147504-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7199143-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-20050182112-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1480975-A2 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-12-01 | — | — | EP | disclosed |
| EP-1286998-B1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| WO-2003072576-A2 | OXAZOLIDINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
| EP-1286998-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081403-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, TBCD, IL17A | MAOA 1190/4885CALML3 3683/4885MAOB 689/4885 |
| US-20050182112-A1 | Chemical compounds | CYP8B1, H1-0, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOA 470/4885CALML3 4065/4885MAOB 355/4885 |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | MAOA 1576/4885CALML3 3848/4885MAOB 992/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | MAOA 2239/4885CALML3 4326/4885MAOB 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.